Airflow Obstruction and Biomarkers of Airway Inflammation During and Following Acute Exacerbations of Childhood Asthma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is a longitudinal single-center pilot study designed to describe changes in lung function and levels of noninvasive biomarkers of airway inflammation in children ages 6-18 years over two months following hospitalization for an acute exacerbation of asthma. Forty children ages 6-18 years with asthma who are admitted to Children's Hospital and Regional Medical Center (GCRC) for an asthma exacerbation will be enrolled and complete an initial study visit prior to hospital discharge. Children with asthma will be recruited from the inpatient medical unit. During their initial visit subjects will undergo a clinical assessment and perform spirometry to measure lung function. In addition, exhaled nitric oxide (eNO) concentration will be measured and a sample of exhaled breath condensate (eBC) will be collected during 20 minutes of tidal breathing. Breath condensate will be analyzed to determine the concentration of cysteinyl leukotrienes (CysLT), an important mediator of airway inflammation in asthma. Subjects with asthma will return to the GCRC pediatric satellite at Seattle Children's Hospital for follow-up study visits at 1 week, 2 weeks, and 4 weeks following hospital discharge. During follow-up visits subjects will complete a questionnaire regarding symptoms and medication use since the most recent study visit, will perform spirometry, and have eNO concentration measured and breath condensate collected for CysLT analysis.
The aims of this observational study are to:
- Assess the association of levels of exhaled nitric oxide and cysteinyl leukotrienes in breath condensate with measures of airflow obstruction (FEV1) and asthma symptoms during, and at one, two, and four weeks following hospital discharge for asthma exacerbation.
- Compare levels of exhaled nitric oxide and cysteinyl leukotrienes in breath condensate from children ages 6-18 years hospitalized for status asthmaticus to levels from age-matched healthy control subjects without asthma.
| Condition |
|---|
|
Asthma |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Airflow Obstruction and Biomarkers of Airway Inflammation During and Following Acute Exacerbations of Childhood Asthma |
- FEV1 [ Time Frame: 1 month ] [ Designated as safety issue: No ]
- FEF25-75 [ Time Frame: 1 month ] [ Designated as safety issue: No ]
- exhaled nitric oxide concentration [ Time Frame: 1 month ] [ Designated as safety issue: No ]
- Breath condensate cysteinyl leukotriene concentration [ Time Frame: 1 month ] [ Designated as safety issue: No ]
- albuterol use [ Time Frame: 1 month ] [ Designated as safety issue: No ]
- school absence [ Time Frame: 1 month ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Exhaled breath condensate
| Enrollment: | 80 |
| Study Start Date: | January 2006 |
| Study Completion Date: | March 2010 |
| Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| Asthmatic |
| Healthy Control |
Eligibility| Ages Eligible for Study: | 6 Years to 18 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
children ages 6-18 years hospitalized for an asthmat exacerbation, similar aged healthy control children
Inclusion Criteria:
Asthma Group
- At least a one-year history of physician diagnosed asthma
- Enrollment within 48 hours of hospitalization, and prior to hospital discharge, for an acute asthma exacerbation.
- Age 6 - 18 years.
- Birth at ≥ 36 weeks gestation.
- Ability to perform acceptable and reproducible spirometry meeting American Thoracic Society guidelines.
Control Group
- Age 6 - 18 years.
- No prior history of asthma.
- Birth at ≥ 36 weeks gestation.
- Ability to perform acceptable and reproducible spirometry meeting American Thoracic Society guidelines.
Exclusion Criteria:
Asthma Group
- History of daily oral steroid use during the month before treatment for the current exacerbation.
- Use of a leukotriene antagonist.
- Birth at ≥ 36 weeks gestation.
Control Group
- History of asthma or reactive airway disease.
- History of a prior illness with wheezing.
- History of chronic cough (daily over the month prior to enrollment).
- History of allergic rhinitis.
- History of atopic dermatitis.
- History of food allergies.
- A URI or episode of sinusitis within 3 weeks of study entry.
Contacts and Locations| United States, Washington | |
| Seattle Children's Hospital | |
| Seattle, Washington, United States, 98115 | |
| Principal Investigator: | Jason S Debley, MD, MPH | Seattle Children's Hospital |
More Information
No publications provided
| Responsible Party: | Jason Debley, MD, MPH, Seattle Chidlren's Hospital |
| ClinicalTrials.gov Identifier: | NCT01227070 History of Changes |
| Other Study ID Numbers: | SCH IRB 11798, IRUSBUPR0055 |
| Study First Received: | October 20, 2010 |
| Last Updated: | October 20, 2010 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Seattle Children's Hospital:
|
Asthma, hospitalization, children, exhaled nitric oxide, lung function, breath condensate, cysteinyl leukotrienes |
Additional relevant MeSH terms:
|
Asthma Inflammation Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Pathologic Processes |
ClinicalTrials.gov processed this record on June 18, 2013